A.T. Omar ¹, N. A. Kabildina ¹, E. V. Kruk ¹, A. M. Telmanov ¹, Zh.K. Kabildin ¹

1. «Karaganda Medical University» Non-profit JSC, Karaganda, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2023-2-68-53-58

UDC: 618.19-006:615.277.3

Year: 2023 issure: 68 number: 2 pages: 53-58

Download PDF:

ABSTRACT

Relevance: Breast cancer is the most common cancer among women. Modern treatment of locally advanced breast cancer requires a multidisciplinary approach, including local treatment: surgical and radiotherapy, systemic treatment, and a wide range of medications. The importance of systemic therapy is to improve relapse-free survival based on the control of micrometastases with the potential to spread throughout the body.
Systemic therapy for operable breast cancer includes adjuvant therapy and neoadjuvant therapy. Hormone therapy, chemotherapy, and targeted therapy represent systemic therapy, which can be prescribed individually or in combination.
For the most effective breast cancer treatment, tumors are classified into subtypes depending on the expression of biological markers. The presence of expression of the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the rate at which tumor cells divide are determined by determining the Ki67.
It is known that neoadjuvant chemotherapy (NCT) has clinical significance in locally advanced and inoperable breast cancer. NCT increases the frequency of organ-preserving operations and the overall survival rate when a complete pathomorphological regression of the tumor (pCR) is achieved.
The study aimed to conduct a literature review of previously published publications on the effectiveness and expediency of neoadjuvant chemotherapy for breast cancer.
Methods: The search and analysis of scientific publications were carried out in the databases Web of Science, Pubmed, and Scopus for ten years, from 2013 to 2023. According to the search, about 3000 articles were found, and 39 sources were left during the selection according to the inclusion and exclusion criteria
Results: Efficiency of NСT depending on different immunophenotypes in breast cancer patients was established. Tumor response was assessed according to RECIST criteria. A complete pathological response was observed more often in more aggressive subtypes of breast cancer – Her2-positive and triple-negative cancer. The relationship between pCR and long-term outcomes – OS and DFS have also been established.
Conclusion: Neoadjuvant chemotherapy is a systemic treatment of breast cancer, the main purpose of which is to reduce the size of the tumor for the possibility of performing organ-preserving surgery, as well as to increase the overall and relapse-free survival rates. NCT allows for evaluating the effectiveness of therapy in vivo and using alternative treatment regimens without tu-mor response to the therapy.
Keywords: breast cancer, neoadjuvant chemotherapy.

List of sources used:

1. Shien T., Iwata H. Adjuvant and neoadjuvant therapy for breast cancer // Japan. J. Clin. Oncol. – 2020. – Vol. 3 (50). – P. 225–229. https://doi.org/10.1093/jjco/hyz213
2. Семиглазов В.Ф., Нургазиев К.Ш., Семиглазов В.В., Дашян Г.А., Палтуев Р.М., Семиглазова Т.Ю., Криворотько П.В., Николаев К.С. Общие рекомендации по лечению раннего рака молочной железы St. Gallen-2015, адаптированные экспертами Российского общества онкомаммологов // Опухоли Жен. Репрод. Системы. – 2015. – Т. 11, №3 [Semiglazov V.F., Nurgaziev K.Sh., Semiglazov V.V., Dashyan G.A., Paltuev R.M., Semiglazova T.Yu., Krivorot’ko P.V., Nikolaev K.S. Obshhie rekomendacii po lecheniyu rannego raka molochnoĭ zhelezy St. Gallen-2015, adaptirovannye e’kspertami Rossiĭskogo obshhestva onkomammologov // Opuxoli Zhen. Reprod. Sistemy. – 2015. – T. 11, №3 (in Russ.)]. https://doi.org/10.17650/1994-4098-2015-11-3-43-60
3. Рак молочной железы: Клинический протокол диагностики и лечения. Утв. ОККМУ МЗ РК, протокол №174 от 21 ноября 2022 г. [Rak molochnoj zhelezy: Klinicheskij protokol diagnostiki i lecheniya. Utv. OKKMU MZ RK, protokol №174 ot 21 noyabrya 2022 g. (in Russ.). https://online.zakon.kz/Document/?doc_id=32210256. 01.06.2023.
4. Shintia C., Endang H., Diani K. Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL // Malaysian J. Pathol. – 2016. – Vol. 38(1). – P. 25-32. https://doi.org/10.2147/dddt.s253961
5. Buchholz T.A., Mittendorf E.A., Hunt K.K. Surgical considerations after neoadjuvant chemotherapy: breast conservation therapy // JNCI Monographs. – 2015. – Vol. 51. – P. 11-14. https://doi.org/10.1093%2Fjncimonographs%2Flgv020
6. Piotrzkowska-Wróblewska H., Dobruch-Sobczak K., Klimonda Z., Karwat P., Roszkowska-Purska K., Gumowska M., Litniewski J. Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter // PLoSOne. – 2019. – Vol. 14(3). – Art. no. e0213749. https://doi.org/10.1371/journal.pone.0213749
7. von Minckwitz G., Blohmer J. U., Costa S. D. , Denkert C., Eidtmann H., Eiermann W., Gerber B., Hanusch C., Hilfrich J., Huober J. Response- guided neoadjuvant chemotherapy for breast cancer // J. Clin. Oncol. – 2013. – Vol. 31(29). – Р. 3623-3630.
8. Spring L.M. , Fell G., Arfe A., Sharma C., Greenup R., Reynolds K.L., Smith B.L., Alexander B., Moy B., Isakoff S.J., Parmigiani G., Trippa L., Bardia A. Pathological complete responseafter neoadjuvant chemotherapy and impact on breast cancer recur-rence and survival: a comprehensive meta-analysis // Clin. Cancer Res. – 2020. – Vol. 26(12). – P. 2838-2848. https://doi.org/10.1158/1078-0432.ccr-19-3492
9. Krishnan Y., Alawadhi S. A., Sreedharan P. S., Gopal M., Thuruthel S. Pathological responses and long-term outcome analysis after neoadjuvant chemotherapy in breast cancer patients from Kuwait over a period of 15 years // Ann. Saudi Med. – 2013. – Vol. 33(5). – P. 443–450. https://doi.org/10.5144/0256-4947.2013.443
10. Schwartz L.H., Litière S., de Vries E., Ford R., Gwyther S., Mandrekar S., Shankar L., Bogaerts J., Chen A., Dancey J., Hayes W., Hodi F.S., Hoekstra O.S., Huang E.P., Lin N., Liu Y., Therasse P., Wolchok J.D., Seymour L. RECIST 1.1-update andclarification: from the RECIST committee // European Journal of Cancer. – 2016. – Vol. 62. – P. 132–137. https://doi.org/10.1016/j.ejca.2016.03.081
11. Schwartz L.H., Seymour L., Litière S., Ford R., Gwyther S., Mandrekar S., Shankar L., Bogaerts J., Chen A., Dancey J., Hayes W., Hodi F.S., Hoekstra O.S., Huang E.P., Lin N., Liu Y., Therasse P., Wolchok J.D., Seymour L. RECIST 1.1 – standardization and disease-specific adaptations: perspectives from the RECIST working group // Eur. J. Cancer. – 2016. – Vol. 62. – P. 138–145. https://doi.org/10.1016/j.ejca.2016.03.082
12. Litière S., Collette S., de Vries E. G., Seymour L., Bogaerts J. RECIST – learning from the past to build the future // Nat. Rev. Clin. Oncol. – 2017. – Vol. 14(3). – P. 187–192. https://doi.org/10.1038/nrclinonc.2016.195
13. Fukada I., Araki K., Kobayashi K., Shibayama T., Takahashi S., Gomi N., Kokubu Y., Oikado K., Horii R., Akiyama F., Iwase T., Ohno S., Hatake K., Sata N., Ito Y. Pattern of tumor shrinkage during neoadjuvant chemotherapy is associated with prognosis in low- grade luminal early breast cancer // Radiology. – 2018. – Vol. 286(1). – P. 49–57. https://doi.org/10.1148/radiol.2017161548
14. Eom H.J., Cha J.H., Choi W.J., Chae E.Y., Shin H.J., Kim H.H. Predictive clinicopathologic and dynamic contrast- enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple- negative breast cancer // AJR. – 2017. – Vol. 208(6). – P. W225-W230. https://doi.org/10.2214/ajr.16.17125
15. Rauch G.M., Adrada B.E., Kuerer H.M., van la Parra R.F., Leung J.W., Yang W.T. Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer // AJR. – 2017. – Vol. 208(2). – P. 290–299. https://doi.org/10.2214/ajr.16.17223
16. Li H., Yao L., Jin P., Hu L., Li X., Guo T., Yang K. MRI and PET/CT for evaluation of thepathological response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis // Breast (Edinburgh, Scotland). – 2018. – Vol. 40. – P. 106–115. https://doi.org/10.1016/j.breast.2018.04.018
17. van der Noordaa M.E.M., van Duijnhoven F.H., Straver M.E., Groen E.J., Stokkel M., Loo C.E., Elkhuizen P.H.M., Russell N.S., Vrancken Peeters M.T.F.D. Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET/CT and the MARI procedure // Ann. Surg. Oncol. – 2018. – Vol. 25(6). – P. 1512–1520. https://doi.org/10.1245/s10434-018-6404-y
18. Christin O.L., Kuten J., Even-Sapir E., Klausner J., Menes T.S. Node positive breast cancer: concordance between baseline PET/CT and sentinel node assessment after neoadjuvant therapy // Surg. Oncol. – 2019. – Vol. 30. – P. 1-5. https://doi.org/10.1055/s-0043-111589
19. Mcdonald E.S., Clark A.S., Tchou J., Zhang P., Freedman G.M. Clinical Diagnosis and Management of Breast Cancer // J. Nucl. Med. – 2016. – Vol. 1 (57). – P. 9S-16S. https://doi.org/10.2967/jnumed.115.157834
20. Evans A., Whelehan P., Thompson A., Purdie C., Jordan L., Macaskill J., Waugh S., Fuller-Pace F., Brauer K., Vinnicombe S. Prediction of pathological complete response to neoadjuvant chemotherapy for primary breast cancer comparing interim ultrasound, shear wave elastography and MRI // Ultraschall Med. – 2018. – Vol. 39(4). – P. 422–431. https://doi.org/10.1055/s-0043-111589
21. Asaoka M., Gandhi S., Ishikawa T., Takabe K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future // Breast Cancer: Basic Clin. Res. – 2020. – Vol. 14. – Art. no. 117822342098037. https://doi.org/10.1177%2F1178223420980377
22. Nekljudova V., Loibl S., von Minckwitz G., Schneeweiss A., Glück S., Crane R., Li H., Luo X. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC) // Contemp. Clin. Trial. – 2018. – Vol. 71. – P. 194-198. https://doi.org/10.1016/j.cct.2018.06.016
23. Rapoport B.L., Demetriou G.S., Moodley S.D., Benn C.A. When and how do I use neoadjuvant chemotherapy for breast cancer? // Curr. Treat. Opt. Oncol. – 2014. – Vol. 15. – P. 86-98. https://doi.org/10.1007/s11864-013-0266-0
24. Barchiesi G., Mazzotta M., Krasniqi E., Pizzuti L., Marinelli D., Capomolla E., Sergi D., Amodio A., Natoli C., Gamucci T., Vizza E., Marchetti P., Botti C., Sanguineti G., Ciliberto G., Barba M., Vici P. Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives // Int. J. Mol. Sci. – 2020. – Vol. 21. – P. 3528. https://doi.org/10.3390/ijms21103528
25. von Minckwitz G., Huang C.S., Mano M.S., Loibl S., Mamounas P.E., Untch M., Wolmark N., Rastogi P., Fischer H.H., Lam L.H., Tesarowski D., Smitt M., Douthwaite H., Singel S.M., Geyer Jr. C.E.; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer // New Engl. J. Med. – 2019. – Vol. 380. – P. 617-628. https://doi.org/10.1200/jco.2007.14.4147
26. Abdel-Razeq H., Abu Rous F., Abuhijla F., Abdel-Razeq N., Edaily S. Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects // Clin. Interv. Aging. – 2022. – Vol. 17. – P. 1445-1460. https://doi.org/10.2147/CIA.S365497
27. Gerber B., Loibl S., Eidtmann H., Rezai M., Fasching P. A., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Kreienberg R., Nekljudova V., Untch M., von Minckwitz G., German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline- taxane- based chemotherapy in 678 triple- negative primary breast cancers; results from the geparquinto study (GBG 44) // Ann. Oncol. – 2013. – Vol. 24. – P. 2978-2984. https://doi.org/10.1093/annonc/mdt361
28. Delgado J., Vleminckx C., Sarac S., Sosa A., Bergh J., Giuliani R., Enzmann H., Pignatti F. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer // ESMO Open. – 2021. – Vol. 6(2). – P. 100074. https://doi.org/10.1016/j.esmoop.2021.100074
29. I-SPY2 Trial Consortium, Yee D., DeMichele A.M., Yau C., Isaacs C., Symmans W.F., Albain K.S., Chen Y.Y., Krings G., Wei S., Harada S., Datnow B., Fadare O., Klein M., Pambuccian S., Chen B., Adamson K., Sams S., Mhawech-Fauceglia P., Magliocco A., Berry D.A. Association of event-free and distant recurrence-free survival with individual- level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial // JAMA Oncol. – 2020. – Vol. 6. – P. 1355-1362. https://doi.org/10.1001/jamaoncol.2020.2535
30. Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im. S.A., Masuda N., Colleoni M., DeMichele A., Loi S., Verma S. Fulvestrant plus palbociclib vs fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2- negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomized controlled trial // Lancet Oncol. – 2016. – Vol. 17. – P. 425–439. https://doi.org/10.1016/s1470-2045(15)00613-0
31. Goetz M.P., Toi M., Campone M., Sohn J., Paluch-Shimon S., Huober J., Park I.H., Tredan O., Chen S.-C., Manso L. MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer // J. Clin. Oncol. – 2017. – Vol. 35. – P. 3638–3646. https://doi.org/10.1200/jco.2017.75.6155.
32. Masuda N., Lee S.J., Ohtani S., Lee E., Yokota I., Kuroi K., Im S., Park B., Kim S., Yanagita Y., Ohno S. Adjuvant capecitabine for breast cancer after preoperative chemotherapy // New Engl. J. Med. – 2017. – Vol. 376. – P. 2147-2159. https://doi.org/10.1056/nejmoa1612645
33. Wang H., Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer // Drug Des., Devel. Ther. – 2020. – Vol. 14. – P. 2423-2433. https://doi.org/10.2147/dddt.s253961
34. Minckwits G., Procter M., Azambuja E., Zardavas D., Benyunes M., Viale G., Suter T., Arahmani A., Rouchet N., Clark E., Knott A., Lang I., Levy C., Yardley D. A., Bines J., Gelber R. D., Baselga J., APHINITY Steering Committee and Investigators. Adjuvant pertuzumaband trastuzumab in early HER2-positeve breast cancer // New Engl. J. Med. – 2017. – Vol. 377(2). – P. 122–131. https://doi.org/10.1056/nejmoa1703643
35. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomized trials // Lancet Oncol. – 2018. – Vol. 19. – P. 27-39. https://doi.org/10.1016/s1470-2045(17)30777-5
36. Gnant M., Pfeiler G., Dubsky P. C., Hubalek M., Greil R., Jakesz R., Wette V., Balic M., Haslbauer F., Melbinger E., Bjelic-Radisic V., Artner-Matuschek S., Fitzal F., Marth C., Sevelda P., Mlineritsch B., Steger G. G., Manfreda D., Exner R., Egle D., Austrian Breast and Colorectal Cancer Study Group (2015). Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial // Lancet. – 2015. – Vol. 386(9992). – P. 433-443. https://doi.org/10.1016/S0140-6736(15)60995-3
37. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials // Lancet. – 2015. Vol. 386. – P. 1353-1361. https://doi.org/10.1016/s0140-6736(15)60908-4
38. Gnant M., Pfeiler G., Steger G. G., Egle D., Greil R., Fitzal F., Wette V., Balic M., Haslbauer F., Melbinger-Zeinitzer E., Bjelic-Radisic V., Jakesz R., Marth C., Sevelda P., Mlineritsch B., Exner R., Fesl C., Frantal S., Singer C. F., Austrian Breast and Colorectal Cancer Study Group (2019). Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): Disease-free survival results from a randomized, double-blind, placebo-controlled, phase 3 trial // Lancet Oncol. – 2019. – Vol. 20(3). – P. 339–351. https://doi.org/10.1016/S1470-2045(18)30862-3
39. Tolaney S.M. , Barry W.T., Dang C.T., Yardley D.A., Moy B., Marcom P.K., Albain K.S., Rugo H.S., Ellis M., Shapira I., Wolff A.C., Carey L.A., Overmoyer B.A., Partridge A.H., Guo H., Hudis C.A., Krop I.E., Burstein H.J., Winer E.P. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer // New Engl. J. Med. – 2015. – Vol. 372(2). – P. 134–141. https://doi.org/10.1056/NEJMoa1406281